Sherpa Healthcare Partners

Hongyun Biology is a biotechnology company dedicated to developing new drugs through structural pharmacology. The firm addresses unmet medical needs, particularly those arising from conditions such as cancer drug resistance and other untreatable diseases. By focusing on therapeutic innovation, Hongyun Biology aims to provide patients with access to advanced treatments that improve health outcomes.

Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.

ClinChoice, also known as Fountain Medical Development Ltd, is a contract research organization based in Beijing, China. The company specializes in providing comprehensive, ICH GCP compliant clinical research services to multinational clients in both China and the United States. Its offerings include consulting, project management, regulatory affairs, and clinical operations, as well as central laboratory services. ClinChoice also focuses on site management, biometrics, and designing clinical trials. Additional services encompass the collection, review, assessment, and reporting of adverse events and serious adverse events, along with data and safety monitoring board handling and signal detection services. Founded in 2006, ClinChoice has established itself as a key player in the clinical research sector.

Yuanyin Bio is a biotechnology company focuses on the research and application of circular RNA technology in the field of innovative drugs and therapies, builds a robust pipeline of preventive and therapeutic new drugs, and is dedicated to addressing clinically unmet disease needs. They serve in the field of innovative drugs and therapies. It establishes a pipeline of preventive and therapeutic new drugs and is committed to solving clinically unmet disease needs.

Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields.

Hui-Gene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of treatments for single-gene disorders and has also initiated projects targeting neurodegenerative diseases and vision disorders. By concentrating on these areas, Hui-Gene aims to advance therapeutic options for conditions often tied to genetic anomalies.

UniXell develops cell therapies for the treatment of cancer and neurodegenerative disorders.

Pilot Bio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzyme engineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.

MindRank is an AI-driven biotech company focused on addressing "undruggable" targets in drug discovery. Founded in 2021, the company operates with a team of 35 scientists based in research and development centers in China and the UK. The leadership comprises accomplished academicians from the British Royal Society and former R&D scientists from leading pharmaceutical companies, bringing substantial expertise in drug research and development. MindRank utilizes its proprietary AI platforms to streamline the drug discovery process, enabling the rapid identification of low-cost synthesis routes for potential compounds. The company has successfully developed a small molecule preclinical candidate and initiated IND-enabling studies for its AI-designed drug, both expected to advance to clinical phases. Their innovative approach aims to deliver small molecule medicines that offer distinct clinical benefits.

Starna Therapeutics offers development of innovative drugs with RNA as the core, and has an industry-leading RNA and organ-selective delivery technology platform with independent intellectual property rights; the company has established a rich R&D pipeline , covering infectious disease vaccines, tumor immunity and other fields.

BAKX Therapeutics is a company focused on developing innovative cancer treatments. It specializes in creating orally active therapeutics that target the mitochondrial apoptosis pathway, which plays a crucial role in cell death and cancer progression. By leveraging insights into the dynamic protein structures involved in this pathway, along with advanced structure-based drug design and computational simulations, BAKX aims to enhance the effectiveness and longevity of cancer therapies. The company's approach seeks to provide medical professionals with improved treatment options for cancer patients.

Fuse Biotherapeutics is a biotechnology company focused on developing innovative immune-modulating therapeutics for cancer patients. Established in 2021 and based in Los Angeles, the company employs a rational approach to its therapeutic development, integrating multiple steps of the immune response. This approach aims to harness potent immune responses to target cancer effectively while preserving the natural mechanisms that protect healthy tissues. By prioritizing safety alongside efficacy, Fuse Biotherapeutics seeks to create new treatment options that offer advantages over existing therapies in the cancer treatment landscape.

Sepax Technologie is a biotechnology firm that offers ion exchange, hydrophobic interaction, and method development services.

Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

Wuxi Biortus Biosciences Co. Ltd. is a contract research organization based in Jiangyin, China, specializing in research and development services that support drug discovery. Founded in 2009, the company offers a range of services including recombinant protein production, in vitro assays and screening, medicinal chemistry, structural biology, and target validation. These services are designed to assist pharmaceuticals, biotechnology firms, and research institutions in achieving their drug discovery objectives. Biortus has established five advanced research platforms and has developed innovative techniques, some of which are patented. The company operates as a subsidiary of Jiangsu Shuangliang Group Company Ltd.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Alamar Biosciences develops technologies for the detection and treatment of cancer and other diseases at the earliest possible time. The company was founded in 2018 and is headquartered in Hayward, California.

CashBackApp is a financial technology company that focuses on enhancing customer loyalty for fast-moving consumer goods (FMCG) companies. The platform enables consumers to earn cashback through M-Pesa on their everyday purchases from participating brands and retailers. By partnering with FMCG companies, CashBackApp allows these businesses to quickly implement and manage promotional offers at scale, effectively incentivizing shoppers to purchase products featured on the app. This approach not only fosters customer loyalty but also drives sales through mobile channels, providing a cost-effective solution for retailers looking to engage consumers.

Bota Biosciences designs and develops synthetic bioengineering technology platform for bio-manufacturing. The company develops cloud databases and intelligent control software suitable for biotechnology development and production. Bota Biosciences was founded in 2019 and is based in Hangzhou, China.

Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.

MAXVAX focuses on the development and commercialization of innovative vaccines targeting viral diseases, including rotavirus, shingles, and herpes. By leveraging advanced vaccine technology, the company aims to enhance treatment options within the biotechnology sector. MAXVAX's goal is to provide healthcare professionals with effective tools to improve patient care and outcomes in the fight against these viral infections.

PAQ Therapeutics is a biotechnology company focused on restoring health and curing diseases by harnessing autophagy, the body's natural process for cellular degradation. The company develops a novel class of small-molecule degraders using autophagosome-tethering compound technology. This innovative approach allows these compounds to bind a diverse array of substrates to the autophagy pathway, enabling healthcare providers to create effective treatments for serious diseases where traditional therapeutic options are often limited. Through its research and development efforts, PAQ Therapeutics aims to provide new solutions for patients in need of advanced medical therapies.

HiFiBiO is a biotherapeutics company focused on harnessing the human immune system to address diseases, particularly cancer and autoimmune disorders. Founded in 2013 and based in Paris, the company specializes in proprietary single-cell technologies that facilitate drug and biomarker discovery and development. HiFiBiO's platform combines extensive biological knowledge with advanced single-cell profiling techniques, allowing for the rapid identification and advancement of antibody drugs. Through partnerships with both industry and academic institutions, HiFiBiO aims to promote open innovation and enhance patient outcomes by unlocking the therapeutic potential of the immune system.

Shanghai Xisoft Technology Co., Ltd. specializes in the development of mobile applications and online solutions focused on hospital operation management. Founded in 2018 and headquartered in Shanghai, the company offers a range of products, including the Xisoft Hospital Operation Management System (HRP), which serves as an information-sharing platform for managing hospital resources. Additionally, the Xiaoxi Handheld HRP is a mobile application that consolidates various hospital functions, such as contact management, salary inquiries, project management, and conference coordination. The Xiyun Platform further enhances hospital management by providing data extraction and calculation services. With a growing presence through offices in multiple cities across China, XiSoft aims to improve the efficiency and effectiveness of hospital operations.

MindRank is an AI-driven biotech company focused on addressing "undruggable" targets in drug discovery. Founded in 2021, the company operates with a team of 35 scientists based in research and development centers in China and the UK. The leadership comprises accomplished academicians from the British Royal Society and former R&D scientists from leading pharmaceutical companies, bringing substantial expertise in drug research and development. MindRank utilizes its proprietary AI platforms to streamline the drug discovery process, enabling the rapid identification of low-cost synthesis routes for potential compounds. The company has successfully developed a small molecule preclinical candidate and initiated IND-enabling studies for its AI-designed drug, both expected to advance to clinical phases. Their innovative approach aims to deliver small molecule medicines that offer distinct clinical benefits.

Appia Bio is an early-stage biotechnology company located in Los Angeles, California, dedicated to the discovery and development of engineered allogeneic cell therapies for various medical conditions. The company utilizes its ACUA technology platform to harness the biology of lymphocyte development, employing chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering. This approach enables the generation of CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs). By maturing and scaling healthy stem cells into invariant T-cell therapies, Appia Bio aims to provide safe and targeted cancer treatments, offering physicians access to allogeneic off-the-shelf cell therapies that can increase patient access to innovative treatments.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

EdiGene is dedicated to the development of genome editing technology for human health. Genome editing technology enables the targeted modification of genetic information in human cells, including gene knockout, knock-in and targeted mutations. They aim at providing the high quality products and services for the patients, the pharmaceutical industry, and the scientific research community with the most advanced genome editing technology.EdiGene innovates and applies genome editing technology to developing human therapeutic products. Their therapeutic approach is to treat diseases at the molecular level, making gene therapy safer and more effective.

Brattea is a medical device research and development company specializing in renal denervation products aimed at treating conditions such as hypertension, cancer pain, and diabetes. The company develops interventional devices, including renal artery ablation catheters and radiofrequency ablation equipment, as well as medical mapping systems. These products are designed to address a range of health issues, including refractory hypertension, obstructive sleep apnea, kidney disease, and heart failure. Brattea is committed to providing reliable medical solutions that enhance patient care and improve health outcomes.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

Visen Pharmaceuticals is a biotechnology company dedicated to the development and commercialization of innovative endocrine drugs. The company aims to address significant unmet medical needs for patients in Greater China, focusing specifically on endocrine treatment solutions. By leveraging its expertise in biotechnology, Visen Pharmaceuticals seeks to improve patient outcomes through the creation of effective therapies in the field of endocrinology.

Bota Biosciences designs and develops synthetic bioengineering technology platform for bio-manufacturing. The company develops cloud databases and intelligent control software suitable for biotechnology development and production. Bota Biosciences was founded in 2019 and is based in Hangzhou, China.

Bota Biosciences designs and develops synthetic bioengineering technology platform for bio-manufacturing. The company develops cloud databases and intelligent control software suitable for biotechnology development and production. Bota Biosciences was founded in 2019 and is based in Hangzhou, China.

Bota Biosciences designs and develops synthetic bioengineering technology platform for bio-manufacturing. The company develops cloud databases and intelligent control software suitable for biotechnology development and production. Bota Biosciences was founded in 2019 and is based in Hangzhou, China.

Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

Hongyun Biology is a biotechnology company dedicated to developing new drugs through structural pharmacology. The firm addresses unmet medical needs, particularly those arising from conditions such as cancer drug resistance and other untreatable diseases. By focusing on therapeutic innovation, Hongyun Biology aims to provide patients with access to advanced treatments that improve health outcomes.

Nanovision Technology, based in the Zhongguancun Yongfeng high-tech industrial base with an additional subsidiary in Chengdu, specializes in high-speed and high-precision radiology imaging. The company focuses on the development of static CT, X-ray CMOS detectors, and X-ray imaging software. Notably, Nanovision created China's first self-developed CMOS flat panel detector, known as the Merak series. Its products are applicable in various sectors, including medical, industrial, and security, offering advanced technological support both domestically and internationally. With a significant research and development foundation, Nanovision is positioned as a key player in the radiation imaging industry.

Shanghai Kechow Pharma, Inc. is a biopharmaceutical company established in 2014 and headquartered in Shanghai, China. The company specializes in the discovery of targeted small molecule drugs, aiming to develop innovative therapies that improve upon existing treatments. KeChow Pharma collaborates with various partners to co-develop its drug candidates, emphasizing a commitment to advancing healthcare through novel therapeutic solutions.

Hui-Gene Therapeutics Co., Ltd. is a biotechnology company based in Shanghai, China, founded in 2018. The company specializes in the research and development of treatments for single-gene disorders and has also initiated projects targeting neurodegenerative diseases and vision disorders. By concentrating on these areas, Hui-Gene aims to advance therapeutic options for conditions often tied to genetic anomalies.

Guoke Hengtai (Beijing) Medical Technology Co., Ltd. was established in February 2013 and is affiliated to Oriental Science and Technology Holding Group Co., Ltd. (hereinafter referred to as “Oriental Instrument”), a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. It is headquartered in Yizhuang Economic and Technological Development Zone, Beijing. . Since the establishment of Guoke Hengtai for 4 years, the company has experienced two rounds of investment in A and B, and its performance has continued to grow at a high speed, with a compound annual growth rate of over 50%. In 2017, the company officially launched the IPO listing journey.

Hangzhou Joinhealth Technology Co., Ltd. specializes in developing software solutions for medical follow-up and post-hospital management. Founded in 2015 and headquartered in Hangzhou, China, the company offers a range of products including systems for hospital follow-up, VIP customer management, chronic disease management, and maternal and child health. Joinhealth Technology integrates artificial intelligence and advanced technologies like the Internet and Internet of Things to enhance patient management. By shifting the focus from disease treatment to comprehensive disease management, the company facilitates intelligent management of patients throughout their healthcare journey, from hospital care to home and potential re-admission.

Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

Developer and researcher of advanced directional protein renaturation technology. The company uses advanced technologies such as high-throughput protein re-screening and purification technology platform, fixed point protein coupling design platform, high-throughput protein drug formulation development platform in their research, enabling the development of more effective protein-based drugs.

Yosemite Clinic is a multidisciplinary medical center located in Central Pudong, Shanghai, offering a wide range of walk-in services in a modern and well-equipped environment. The clinic provides specialties including family medicine, internal medicine, gynecology, pediatrics, rehabilitation, sports medicine, dentistry, ophthalmology, dermatology, and medical cosmetology. It is particularly noted for its focus on Minimally Invasive Surgery and Ambulatory Surgery. The facility is equipped with advanced medical imaging technology, including CT, X-ray, and ultrasound, alongside a fully operational laboratory and pharmacy. The clinic's diverse team of healthcare professionals hails from both China and around the world, allowing them to offer services in multiple languages such as English, Japanese, Malay, Mandarin Chinese, and Cantonese, ensuring comprehensive care for a diverse patient population.

Beijing Immunochina Pharmaceuticals Co., Ltd. is a clinical-stage biotechnology company focused on the research and development of chimeric antigen receptor (CAR) T-cell therapies and a lentiviral vector manufacturing platform aimed at treating malignant tumors. The company's pipeline includes therapies targeting CD19, which is prevalent in various B-lineage malignancies such as acute B-cell lymphoblastic leukemia and non-Hodgkin's lymphoma; B cell maturation antigen (BCMA) for multiple myeloma; and CD123, associated with leukemia blasts and stem cells. Additionally, Immunochina is conducting clinical studies on CAR-T cells for relapsed and refractory non-Hodgkin's lymphoma. Founded in 2015 and based in Beijing, the company also engages in the production of cell injections, cell therapy drugs, and offers services related to medical technology development and clinical research.

Hongyun Biology is a biotechnology company dedicated to developing new drugs through structural pharmacology. The firm addresses unmet medical needs, particularly those arising from conditions such as cancer drug resistance and other untreatable diseases. By focusing on therapeutic innovation, Hongyun Biology aims to provide patients with access to advanced treatments that improve health outcomes.